Fate Therapeutics Inc (FATE)

91.42 +1.70  +1.89% NASDAQ Mar 1, 08:00 USD
View Full Chart
Price Chart
View All FATE News

News

View All Events

Events

Date Type Description
05/11/2021 Earnings Fate Therapeutics Inc First Quarter Earnings Results for 2021
05/11/2021 Misc Fate Therapeutics Inc First Quarter Earnings Conference Call for 2021
02/24/2021 Earnings Fate Therapeutics Inc Fourth Quarter Earnings Result for 2020
02/24/2021 17:00 EST Misc Fate Therapeutics Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 17:00 EST Misc Fate Therapeutics Inc Third Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Fate Therapeutics Inc Third Quarter Earnings Result for 2020
08/05/2020 17:30 EDT Misc Fate Therapeutics Inc Second Quarter Earnings Conference Call for 2020
08/05/2020 Earnings Fate Therapeutics Inc Second Quarter Earnings Result for 2020
05/11/2020 17:00 EDT Misc Fate Therapeutics Inc First Quarter Earnings Conference Call for 2020
05/11/2020 Earnings Fate Therapeutics Inc First Quarter Earnings Result for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.fatetherapeutics.com
  • Investor Relations URL: http://ir.fatetherapeutics.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: May. 11, 2021
  • Last Earnings Release: Feb. 24, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Top Fund Holders

Symbol Name Weighting
IDNA iShares Genomics Immnlgy & Hlthcr ETF 5.66%
SBIO ALPS Medical Breakthroughs ETF 3.88%
PTH Invesco DWA Healthcare Momentum ETF 3.85%
ARKG ARK Genomic Revolution ETF 3.12%
PJHRX PGIM Jennison Health Sciences R 2.11%
RSEKX Victory RS Small Cap Growth R 2.02%
FRBRX Franklin Biotechnology Discovery R6 1.85%
USTCX USAA Science & Technology Class A 1.49%
PGRRX Pioneer Select Mid Cap Growth R 1.33%
FBIOX Fidelity® Select Biotechnology 1.07%
IWO iShares Russell 2000 Growth ETF 0.50%
IWM iShares Russell 2000 ETF 0.23%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.